VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 468 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2015. The put-call ratio across all filers is 0.90 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $171,000 | -40.8% | 11,763 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $289,000 | -21.3% | 11,763 | -35.5% | 0.00% | -33.3% |
| Q2 2016 | $367,000 | -25.7% | 18,238 | 0.0% | 0.01% | -25.0% |
| Q1 2016 | $494,000 | -73.4% | 18,238 | 0.0% | 0.01% | -69.2% |
| Q4 2015 | $1,854,000 | -64.7% | 18,238 | -38.0% | 0.03% | -62.9% |
| Q3 2015 | $5,251,000 | -21.3% | 29,438 | -2.0% | 0.07% | -4.1% |
| Q2 2015 | $6,673,000 | +8.2% | 30,038 | -3.2% | 0.07% | +14.1% |
| Q1 2015 | $6,165,000 | -0.4% | 31,038 | -28.2% | 0.06% | 0.0% |
| Q4 2014 | $6,188,000 | -47.4% | 43,238 | -51.8% | 0.06% | -48.0% |
| Q3 2014 | $11,764,000 | +84.4% | 89,664 | +77.2% | 0.12% | +98.4% |
| Q2 2014 | $6,381,000 | +109.6% | 50,592 | +119.0% | 0.06% | +106.7% |
| Q1 2014 | $3,045,000 | -16.6% | 23,100 | -25.7% | 0.03% | -16.7% |
| Q4 2013 | $3,651,000 | +12.5% | 31,100 | 0.0% | 0.04% | +5.9% |
| Q3 2013 | $3,245,000 | +21.2% | 31,100 | 0.0% | 0.03% | +17.2% |
| Q2 2013 | $2,677,000 | – | 31,100 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |